CA-4948 – Patient Worthy

source: pixabay.com

First Patient Dosed in CA-4948 Trial for Hematologic Malignancies

Post author:Jessica Lynn
Post published:February 16, 2021
Post category:Acute Myeloid Leukemia Cancer Myelodysplastic syndromes

The first patient has been dosed in a Phase 1 clinical trial, which is exploring Curis Inc.'s CA-4948 in conjunction with ibrutinib for hematologic malignancies. Examples of hematologic malignancies include…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More